Entry Point Capital, LLC Taysha Gene Therapies, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 27,027 shares of TSHA stock, worth $57,297. This represents 0.03% of its overall portfolio holdings.
Number of Shares
27,027Holding current value
$57,297% of portfolio
0.03%Shares
3 transactions
Others Institutions Holding TSHA
# of Institutions
119Shares Held
136MCall Options Held
25.9KPut Options Held
24K-
Avoro Capital Advisors LLC New York, NY18.7MShares$39.5 Million0.56% of portfolio
-
Rtw Investments, LP New York, NY14.9MShares$31.7 Million0.48% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$24.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$23 Million0.3% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$19.1 Million1.87% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $103M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...